ATRS Antares Pharma, Inc.

2.76
+0  (1%)
Previous Close 2.72
Open 2.73
Price To book 9.35
Market Cap 428.47M
Shares 155,242,000
Volume 1,153,406
Short Ratio 2.39
Av. Daily Volume 1,081,590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
PDUFA date October 20, 2017.
VIBEX QuickShot
Testosterone deficiency

Latest News

  1. AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
  2. ETFs with exposure to Antares Pharma, Inc. : April 7, 2017
  3. Antares Pharma Announces Poster Presentation of Quickshot Testosterone Data at the Endocrine Society Annual Meeting
  4. Penny Stocks to Watch for April 2017 (ATRS, WRN)
  5. ETFs with exposure to Antares Pharma, Inc. : March 27, 2017
  6. ATRS: 2016 Financial and Operational Results
  7. Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  8. Antares Pharma, Inc. :ATRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  9. Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap Back from Late 2016 Uncertainties
  10. Antares Pharma reports 4Q loss
  11. Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results
  12. Antares Pharma to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Webcast and Conference Call
  13. Antares Pharma to Present at the Cowen and Company 37th Annual Healthcare Conference
  14. Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone
  15. Biotech Acquisitions on the Rise in 2017: Latest Reports on Antares Pharma and ACADIA Pharmaceuticals
  16. Antares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : January 24, 2017
  17. Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : January 23, 2017
  18. ETFs with exposure to Antares Pharma, Inc. : January 20, 2017

SEC Filings

  1. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17688121
  2. 8-K - Current report 17686884
  3. 8-K - Current report 17666521
  4. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17603785
  5. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17596998
  6. 8-K - Current report 17554262
  7. 10-Q - Quarterly report (Sections 13 or 15(d)) 161984157
  8. 8-K - Current report 161982835
  9. 8-K - Current report 161965672
  10. 8-K - Current report 161904469